-
公开(公告)号:CA2241787C
公开(公告)日:2006-04-04
申请号:CA2241787
申请日:1997-01-10
Applicant: BASF AG
Inventor: TESCHENDORF HANS-JURGEN , WICKE KARSTEN , TREIBER HANS-JORG , STARCK DOROTHEA , BLANK STEFAN , UNGER LILIANE
IPC: C07D243/08 , C07D403/14 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
Abstract: The present invention concerns aza- and diazacycloheptane and cyclooctane compounds from the following formula (I) Ar1-A-B-Ar2 wherein Ar1, A, B, and Ar2 have the meanings given in the description. The compounds according to the invention possess a high affinity with the dopamine-D3-receptors and can therefore be used for the treatment o f illness, which react to dopamine-D3-ligands.
-
公开(公告)号:DE59510596D1
公开(公告)日:2003-04-24
申请号:DE59510596
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D277/22 , A61K31/425 , A61K31/426 , A61K31/433 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/54 , C07D277/20 , C07D277/32 , C07D277/36 , C07D277/42 , C07D285/12 , C07D285/125 , C07D285/135 , C07D417/12
Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.
-
43.
公开(公告)号:SK283039B6
公开(公告)日:2003-02-04
申请号:SK23099
申请日:1997-08-22
Applicant: BASF AG
Inventor: STEINER GERD , LUBISCH WILFRIED , BACH ALFRED , EMLING FRANZ , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , BEHL BERTHOLD , KERRRIGAN FRANK , CHEETHAM SHARON
IPC: A61K31/435 , A61K31/519 , A61P25/24 , A61P43/00 , C07D211/00 , C07D239/00 , C07D333/00 , C07D495/14
Abstract: The invention concerns 3-substituted 3,4,5,6,7,8-hexahydro- pyrid3':4,5]thieno-[2,3-d]pyrimidine derivatives of formula (I), their physiologically acceptable salts and use in the therapy.
-
44.
公开(公告)号:SI1025100T1
公开(公告)日:2002-10-31
申请号:SI9830101
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D471/00
-
公开(公告)号:PT994865E
公开(公告)日:2002-08-30
申请号:PT98938687
申请日:1998-07-03
Applicant: BASF AG
Inventor: UNGER LILIANE , TESCHENDORF HANS-JUERGEN , TREIBER HANS-JORG , WICKE KARSTEN , STARCK DOROTHEA , BLANK STEFAN , NEUMANN-SCHULTZ BARBARA , BRIS THEOPHILE-MARIE LE
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of the following formula:where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.
-
公开(公告)号:DK0772603T3
公开(公告)日:2002-07-15
申请号:DK95926898
申请日:1995-07-14
Applicant: BASF AG
Inventor: UNGER LILIANE , TESCHENDORF HANS-JUERGEN , BIALOJAN SIEGFRIED , HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
47.
公开(公告)号:AU749320B2
公开(公告)日:2002-06-20
申请号:AU7917698
申请日:1998-05-29
Applicant: BASF AG
Inventor: STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HANS-JURGEN , GARCIA-LADONA FRANCISCO-JAVIER , EMLING FRANZ
IPC: A61K31/495 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/04
Abstract: PCT No. PCT/EP98/03230 Sec. 371 Date Dec. 6, 1999 Sec. 102(e) Date Dec. 6, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56792 PCT Pub. Date Dec. 17, 19983-Substituted 3,4-dihydrothieno[2,3-d]pyrimidine derivatives of the formula I where R1 and R2 are a hydrogen atom or a C1-C4-alkyl group, R3 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which may be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups, and may contain 1 nitrogen atom, or to a 5- or 6-membered ring, which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it being possible for the linkage between Y and Z also to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.
-
公开(公告)号:AT219063T
公开(公告)日:2002-06-15
申请号:AT95926898
申请日:1995-07-14
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D239/26 , A61K31/505 , A61K31/506 , A61P25/16 , A61P25/24 , A61P25/26 , C07D239/38 , C07D239/46 , C07D239/56 , C07D239/60 , C07D401/00 , C07D401/12
Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号:BG63500B1
公开(公告)日:2002-03-29
申请号:BG10111397
申请日:1997-01-06
Applicant: BASF AG
Inventor: HELLENDAHL BEATE , LANSKY ANNEGRET , MUNSCHAUER RAINER , BIALOJAN SIEGFRIED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN , DRESCHER KARLA
IPC: C07D249/08 , A61K31/41 , A61K31/435 , A61K31/4427 , A61K31/445 , A61K31/505 , A61K31/53 , A61P1/08 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D249/12 , C07D249/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: The invention relates to triazole compounds with the formula where R1 & R2 mean hydrogen or different substituents, A is a two-valent group, B is residue with formula a, b or c and Ar in a given case means substituted phenyl, pyridyl, pyrimidyl or triazinyl. The compounds have higher affinity to dopamine-D3-receptors and can be used for the treatment of diseases which react to dopamine-D3-ligands. 13 claims
-
公开(公告)号:DE59802922D1
公开(公告)日:2002-03-14
申请号:DE59802922
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/519 , A61P1/00 , A61P1/14 , A61P3/04 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D471/00 , C07D471/04
Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
-
-
-
-
-
-
-
-
-